LGD-4033, also called ligandrol, is a non-steroidal selective androgen receptor modulator that binds the androgen receptor with high affinity.
Amounts reported for LGD-4033 are listed under Reported protocols, each with its source and study kind. No amount ladder is inferred from them. This is educational source context, not a protocol or recommendation.
Enter a target amount only from your own reviewed source. The calculator can convert it into concentration, volume and device markings, but it will not infer an amount from product availability or another compound.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
Human study rows are described per source under Reported protocols; they belong to their trial populations and are not a general amount.
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
What published studies and recent community write-ups report about amounts, timing and course length. 4 clinical and 1 community-reported rows, each linked to its source. These are descriptions of what others report, not instructions, and nothing here is medical advice.
| Context | Dose | Frequency | Route | Course | Source |
|---|---|---|---|---|---|
| Clinical4 rows | |||||
| Phase 1 ascending-dose study in healthy men76 healthy men aged 21 to 50, randomised to placebo or one of three doses | 0.1, 0.3 or 1.0 mg | Once daily after an overnight fast, 20 doses given over the period | Oral | 21 days, followed by 5 weeks of observationNo dose on day 2, to allow 48 hours of pharmacokinetic sampling | Journals of Gerontology Series A (PubMed Central)2013 |
| Lean body mass rose dose dependently while fat mass did not change significantly. Total testosterone, sex hormone binding globulin, HDL cholesterol and triglycerides were suppressed dose dependently; free testosterone and FSH fell only at 1.0 mg, and luteinising hormone did not move meaningfully. Hormones and lipids returned to baseline by day 56. No drug-related serious adverse events occurred, and haemoglobin, prostate-specific antigen, transaminases and QT intervals did not change significantly over these three weeks. An earlier single-ascending-dose study had established the safety of up to 22 mg. | |||||
| Phase 2 trial after hip fracture surgery, as VK5211108 patients aged 65 or older recovering from non-elective hip fracture surgery | 0.5, 1.0 or 2.0 mg against placebo | Once daily | Oral | 12 weeks, the longest published human exposureNone described | ClinicalTrials.gov2017 |
| This is a completed randomised, double-blind, quadruple-masked trial registered as NCT02578095 and run by Viking Therapeutics, which licensed the molecule. It remains the only phase 2 study of the compound, and the programme has not advanced to phase 3. | |||||
| Phase 2 reported resultsThe same 108 hip fracture patients | 0.5, 1.0 or 2.0 mg once daily | Once daily | Oral | 12 weeksNone described | Viking Therapeutics2017 |
| Placebo-adjusted lean body mass rose 4.8% at 0.5 mg, 7.2% at 1.0 mg and 9.1% at 2.0 mg, corresponding to 1.6, 2.5 and 3.1 kg. Appendicular lean mass rose 6.1% to 10.2% and mean fat mass fell 2.2% to 6.2%, reaching significance only at 2.0 mg. Six-minute walk distance improved by about 22 metres against placebo at the top dose, on an exploratory endpoint that was not powered for significance. No drug-related serious adverse events were reported. These figures come from the sponsor's announcement rather than a peer-reviewed paper. | |||||
| Reported adverse events outside trials, including liver injuryPublished case reports and adverse event database entries from recreational users | Amounts self-reported by users and often unverifiable; a survey of 2,269 young male gym users found 2.7% reported SARM use, with this compound the most commonly named | Not stated | Oral, usually as a product bought online | Not stated | European Journal of Clinical Pharmacology2023 |
| This review of suspected cases found reports of cholestatic and hepatocellular liver injury attributed to this compound alone and in combination with other SARMs, alongside database entries describing visual impairment, cerebrovascular events, abnormal hormone levels and testicular changes. Because these are spontaneous reports from unregulated products, the true exposure is unknown and the product taken may not have matched its label. | |||||
| Community-reported1 row | |||||
| What is actually in products sold online | Label amount matched laboratory analysis in only 18 of 44 products | Not stated | Products bought from internet suppliers and analysed under anti-doping procedures | Not stated | JAMA (PubMed)2017 |
| Of 44 products sold as selective androgen receptor modulators, 52% contained a SARM at all, this compound among the three that were found. No active compound was detected in 9%, unlabelled substances were present in 25%, and the measured amount differed substantially from the label in 59%. Every milligram figure on a product sold this way is a claim, not a measurement. | |||||
The healthy-volunteer study gave 20 oral doses over three weeks at 0.1 to 1.0 mg a day, then watched participants for five more weeks. Lean mass rose during treatment, hormones and lipids fell, and both returned to baseline by day 56 after dosing stopped.
The hip fracture trial is the longest course ever given to people under supervision, at 0.5 to 2.0 mg once daily for twelve weeks. Lean mass gains were dose dependent and fat mass fell at the top dose. Nothing longer than twelve weeks has been studied in humans.
Liver injury attributed to this compound appears weeks into use of consumer products, typically with jaundice as the first symptom, and generally resolves after the product is stopped. The doses in those reports are self-reported and the products were not verified, which is the central difficulty in reading them.
LGD-4033, also called ligandrol, is a non-steroidal selective androgen receptor modulator that binds the androgen receptor with high affinity and was developed to build muscle and bone with less effect on prostate and skin than testosterone. It has the most substantial human record of any compound in this class sold online: a 21-day phase 1 study in 76 healthy men and a 12-week phase 2 trial in 108 hip fracture patients, both of which increased lean body mass. It has never been approved by any regulator, the FDA has issued warning letters naming it an unapproved prescription drug, and it is prohibited in sport at all times.
These themes describe recurring questions in published research. They are not claims of effectiveness or recommendations for use.
Androgen receptor modulators, myostatin pathways and exercise-mimetic research.
Lean body mass rose dose dependently while fat mass did not change significantly. Total testosterone, sex hormone binding globulin, HDL cholesterol and triglycerides were suppressed dose dependently; free testosterone.
This is a completed randomised, double-blind, quadruple-masked trial registered as NCT02578095 and run by Viking Therapeutics, which licensed the molecule. It remains the only phase 2 study of the compound, and the.
Placebo-adjusted lean body mass rose 4.8% at 0.5 mg, 7.2% at 1.0 mg and 9.1% at 2.0 mg, corresponding to 1.6, 2.5 and 3.1 kg. Appendicular lean mass rose 6.1% to 10.2% and mean fat mass fell 2.2% to 6.2%, reaching.
This review of suspected cases found reports of cholestatic and hepatocellular liver injury attributed to this compound alone and in combination with other SARMs, alongside database entries describing visual.
Of 44 products sold as selective androgen receptor modulators, 52% contained a SARM at all, this compound among the three that were found. No active compound was detected in 9%, unlabelled substances were present in.
Study models remain visible so laboratory and animal findings are not mistaken for established human outcomes.
4 protocol rows on this page come from human trials, trial registrations, regulator labels or reviews of human data. Approval status and populations are stated per row.
1 row record what blogs, vendor write-ups or forums describe for LGD-4033. None has been verified against primary literature.
Sequence, synonyms and registry identifiers as recorded in PubChem, the National Library of Medicine's open chemistry database. Formula, mass and CAS number are summarized at the top of the page.
Ligandrol, LGD-4033, VK-5211, VK5211, UNII 1EJT54415A, CHEMBL5170587, LGD4033
OPSIVAKKLQRWKC-VXGBXAGGSA-N
4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile
8 curated references, each with its journal, year and study model.